The safety evaluation of endoscopic biopsy against patients receiving anticoagulatns and antiplatelet agents.

The safety evaluation of endoscopic biopsy against patients receiving anticoagulatns and antiplatelet agents. - The safety evaluation of endoscopic biopsy during antithrombotic therapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003750

Enrollment

100

Registered

2010-06-16

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Outpatients undergoing gastrointestinal endoscopy during antithrombotic therapy

Interventions

Endoscopic biopsy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (A)Medical need of gastrointestinal endoscopy. (B)Comorbidity requiring antithrombotic therapy. (C)Receiving anticoagulants and/or antiplatelet agents. (D)Informed consent. (E)Performance status(ECOG):0-2. (F)Scheduled blood test about two weeks after biopsy. (G)Outpatient.

Exclusion criteria

Exclusion criteria: (A)Strong possibility of lesions requiring more invasive procedures than biopsy. (B)During hospitalization. (C)Other severe comorbidities. (D)During anticancer chemotherapy. (E)Severe hematological, hepatological, or renal disorder accompanied with hemorrhagic tendency. (F)INR exceeding the upper limit shown in the guideline by Japanese circulation society.

Design outcomes

Primary

Measure	Time frame
Gastrointestinal bleeding during two weeks after biopsy.	—

Countries

Japan

Contacts

Public ContactSatoshi Ono

Graduate School of Medicine, The University of Tokyo. Department of Gastroenterology.

satoshi-tky@umin.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026